COVID, Pneumonia, Viral
Conditions
Keywords
azithromycin, hydroxychloroquine, COVID-19, pneumonia, hospitalization
Brief summary
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone. Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.
Interventions
DRUGfavorable outcome
Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
Sponsors
Centre d'Investigation Clinique et Technologique 805
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* aged over 18 years old * hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry, * admitted outside an intensive care unit, in a medicine ward
Exclusion criteria
* patient opposed to data collected, or who could not consent because of a serious presentation of the pneumonia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Favorable outcome | Assessed within 7 days after admission | After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Risk factors 1 | Assessed at day 1 | Studying if biological abnormalities (lymphocyte count or CRP) at admission were associated with an unfavorable outcome |
| Risk factors 2 | Assessed at day 1 | Studying if comorbidities were associated with an unfavorable outcome |
| Interest of anti-infective agents | From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months | Studying whether any regimen was associated with a favorable outcome (including azithromycin) |
Countries
France
Outcome results
None listed